

SUMO-2 (human, recombinant)  
Cat. # SU202


**Background:** Human recombinant SUMO-2 is produced in *E. coli* and purified to >95% homogeneity. This protein contains no extraneous tags. Vertebrates express three SUMO homologs, SUMO-1 and the closely related SUMO-2/3, which can be conjugated to substrate proteins in a manner analogous to the ubiquitin system<sup>1-3</sup>. Although a fourth SUMO (SUMO-4) has been identified in the genome<sup>4</sup>, it may be an unexpressed pseudogene.

**Application:** For use in conjunction assays using SUMO E1 (Cat. # SU101) and UBE2I (Ubc9; Cat. # UB228H) (see protocol below). SUMO can be conjugated to consensus sequences ( $\psi$ -K-X-D/E;  $\psi$  is any large hydrophobic residue and X is any amino acid) *in vitro* independent of an E3 enzyme. Inclusion of a SUMO E3 can increase the rate of conjugation and/or direct SUMOylation to nonconsensus sites.


**Alternative Names:** Sentrin-2; Small ubiquitin-related modifier 2

**Product Information**

<b>Accession No.:</b>	P61956
<b>Tag:</b>	None
<b>Expression Host:</b>	<i>E. coli</i>
<b>Purity:</b>	≥ 95% by RP-HPLC
<b>Molecular Weight:</b>	10,477.7 Da (calculated)
<b>Physical State:</b>	5mg/ml in PBS
<b>Quantity:</b>	500 µg
<b>Storage:</b>	-80°C. Avoid repeated freeze/thaw cycles



**RP-HPLC**



**Deconvoluted mass spectrum**

All products are for research use only • not intended for human or animal diagnostic or therapeutic uses  
Copyright © 2013 LifeSensors, Inc. All Rights Reserved

---

## References

1. Gareau, J.R. and C.D. Lima, *The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition*. Nat Rev Mol Cell Biol, 2010. **11**(12): p. 861-71.
2. Cubenas-Potts, C. and M.J. Matunis, *SUMO: a multifaceted modifier of chromatin structure and function*. Dev Cell, 2013. **24**(1): p. 1-12.
3. Bettermann, K., et al., *SUMOylation in carcinogenesis*. Cancer Lett, 2012. **316**(2): p. 113-25.
4. Bohren, K.M., et al., *A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus*. J Biol Chem, 2004. **279**(26): p. 27233-8.

All products are for research use only • not intended for human or animal diagnostic or therapeutic uses  
Copyright © 2013 LifeSensors, Inc. All Rights Reserved

**Protocol:**

**E3 Ligase-independent SUMOylation Assay**

- 1) Dilute the following into 10ul SUMOylation Assay Buffer:
  - a. 0.2ug SUMO-1 or SUMO-2/3 (Cat. # SU201)
  - b. 150ng SUMO E1 (Cat. # SU101)
  - c. 200ng UBE2I (Ubc9; Cat. # UB228H)
  - d. 0.2ug target substrate (150nM for a 65kDa protein)
  - e. Add SUMOylation Assay Buffer to bring to 20ul final volume
- 2) Add 1uM of 100mM ATP
- 3) Incubate for 30-60minutes at 30°C
- 4) Stop reaction with 20ul SDS sample buffer
- 5) Denature 3 minutes at 95°C
- 6) Load 20ul onto an SDS-PAGE gel and analyze by Western Blotting. SUMOylation results in a shift in migration of your protein of 20kDa

**SUMOylation Assay Buffer**

20mM HEPES, pH7.3  
 110mM potassium acetate  
 2mM magnesium acetate  
 1mM EGTA  
 1mM DTT  
 0.05% Tween 20  
 0.2mg/ml ovalbumin  
 Optional: 1ug/ml leupeptin, pepstatin, aprotinin

**ATP**

100mM in 20mM HEPES, pH7.4, 100mM MgOAc

All products are for research use only • not intended for human or animal diagnostic or therapeutic uses  
 Copyright © 2013 LifeSensors, Inc. All Rights Reserved